EUVIMEDEUVIMED entdecken
Open Access

Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice

Erik B Faber iD, Nan Wang iD, Kristen John iD, Luxin Sun iD, Henry L Wong iD, David Burban iD, Rawle Francis, Defeng Tian iD, Kwon H Hong, An Yang, Liming Wang iD, Mazen Elsaid und 5 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Erik B Faber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy─Twin Cities, …. Hauptthemen laut MEDLINE: Contraceptive Agents, Male. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although cyclin-dependent kinase 2 (CDK2) is a validated target for both cancer and contraception, developing a CDK2 inhibitor with exquisite selectivity has been challenging due to the structural similarity of the ATP-binding site, where most kinase inhibitors bind. We previously discovered an allosteric pocket in CDK2 with the potential to bind a selective compound and then discovered and structurally confirmed an anthranilic acid scaffold that binds this pocket with high affinity. These allosteric inhibitors are selective for CDK2 over structurally similar CDK1 and show contraceptive potential. Herein, we describe the screening and optimization that led to compounds like EF-4-177 with nanomolar affinity for CDK2. EF-4-177 is metabolically stable, orally bioavailable, and significantly disrupts spermatogenesis, demonstrating this series' therapeutic potential. This work details the discovery of the highest affinity allosteric CDK inhibitors reported and shows promise for this series to yield an efficacious and selective allosteric CDK2 inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contraceptive Agents, MaleMaleHumansAnimalsMiceCyclin-Dependent Kinase 2Structure-Activity RelationshipSperm CountSemenProtein Kinase Inhibitors

Substanzen

Cyclin-Dependent Kinase 2Contraceptive Agents, MaleProtein Kinase InhibitorsCDK2 protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy─Twin Cities, Minneapolis, Minnesota55414, United States.
  • Medical Scientist Training Program, University of Minnesota Medical School─Twin Cities, Minneapolis, Minnesota55455, United States.
  • Drug Discovery Department, Moffitt Cancer Center, Tampa, Florida33612, United States.
  • Department of Pharmacology, University of Minnesota Medical School─Twin Cities, Minneapolis, Minnesota55455, United States.

ORCID-Profile: Erik B Faber, Nan Wang, Kristen John, Luxin Sun, Henry L Wong, David Burban, Defeng Tian, Liming Wang, Nicholas M Levinson, Ernst Schönbrunn, Jon E Hawkinson, Gunda I Georg

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • NICHD NIH HHS
  • National Cancer Institute
  • NIH Office of the Director
  • National Institute of General Medical Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Faber, E. B., Wang, N., John, K., Sun, L., Wong, H. L., Burban, D., Francis, R., Tian, D., Hong, K. H., Yang, A., Wang, L., Elsaid, M., Khalid, H., Levinson, N. M., Schönbrunn, E., Hawkinson, J. E., & Georg, G. I. (2023). Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01731

Vancouver

Faber EB, Wang N, John K, Sun L, Wong HL, Burban D, et al. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01731

BibTeX
@article{Faber2023,
  author = {Faber, Erik B and Wang, Nan and John, Kristen and Sun, Luxin and Wong, Henry L and Burban, David and Francis, Rawle and Tian, Defeng and Hong, Kwon H and Yang, An and Wang, Liming and Elsaid, Mazen and Khalid, Hira and Levinson, Nicholas M and Schönbrunn, Ernst and Hawkinson, Jon E and Georg, Gunda I},
  title = {Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01731}
}
Kostenlos starten →